Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 Motzer, 2015, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J. Clin. Oncol., 33, 1430, 10.1200/JCO.2014.59.0703 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Younes, 2016, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol., 17, 1283, 10.1016/S1470-2045(16)30167-X Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093 Kumar, 2017, Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy, Front. Pharmacol., 8, 49, 10.3389/fphar.2017.00049 Yuan, 2016, Novel technologies and emerging biomarkers for personalized cancer immunotherapy, J Immunother Cancer, 4, 3, 10.1186/s40425-016-0107-3 Ung, 2016, Challenges & perspectives of immunotherapy biomarkers & the histoOncoImmune methodology, Exp. Rev. Precision Med. Drug Dev., 1, 9, 10.1080/23808993.2016.1140005 Kelderman, 2015, Mismatch repair-deficient cancers are targets for anti-PD-1 therapy, Cancer Cell, 28, 11, 10.1016/j.ccell.2015.06.012 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Akhmetov, 2015, Market access advancements and challenges in drug-companion diagnostic test Co-development in europe, J. Pers Med., 5, 213, 10.3390/jpm5020213 Masucci, 2016, Validation of biomarkers to predict response to immunotherapy in cancer: volume I − pre-analytical and analytical validation, J. Immunother. Cancer, 4, 76, 10.1186/s40425-016-0178-1 Lee, 2006, Fit-for-purpose method development and validation for successful biomarker measurement, Pharm. Res., 23, 312, 10.1007/s11095-005-9045-3 Dobbin, 2016, Validation of biomarkers to predict response to immunotherapy in cancer: volume II − clinical validation and regulatory considerations, J. Immunother. Cancer, 4, 77, 10.1186/s40425-016-0179-0 Fridlyand, 2013, Considerations for the successful co-development of targeted cancer therapies and companion diagnostics, Nat. Rev. Drug Discov., 12, 743, 10.1038/nrd4101 Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J. Natl. Cancer Inst., 101, 1446, 10.1093/jnci/djp335 Antoniou, 2016, Biomarker-Guided adaptive trial designs in phase II and phase III: a methodological review, PLoS One, 11, e0149803, 10.1371/journal.pone.0149803 https://www.cdc.gov/genomics/gtesting/acce/2010. Lyman, 2016, Biomarker tests for molecularly targeted therapies: laying the foundation and fulfilling the dream, J. Clin. Oncol., 34, 2061, 10.1200/JCO.2016.67.3160 Vansteenkiste, 2016, Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 17, 822, 10.1016/S1470-2045(16)00099-1 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 Gettinger, 2015, Overall survival and long-Term safety of nivolumab (Anti-Programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-Small-Cell lung cancer, J. Clin. Oncol., 33, 2004, 10.1200/JCO.2014.58.3708 Brahmer, 2017, Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors, Cancer Res., 77, CT077, 10.1158/1538-7445.AM2017-CT077 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Horn, 2017, Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057), J. Clin. Oncol., 10.1200/JCO.2017.74.3062 Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Casadevall, 2017, Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples, Clin. Lung Cancer, 18, 682, 10.1016/j.cllc.2017.04.014 McLaughlin, 2016, Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer, JAMA Oncol., 2, 46, 10.1001/jamaoncol.2015.3638 Ilie, 2016, Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol., 27, 147, 10.1093/annonc/mdv489 Uruga, 2017, Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases, J. Thorac. Oncol., 12, 458, 10.1016/j.jtho.2016.10.015 Noman, 2014, PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation, J. Exp. Med., 211, 781, 10.1084/jem.20131916 Ikeda, 2016, PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer, J. Thorac. Oncol., 11, 62, 10.1016/j.jtho.2015.09.010 Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Schildhaus, 2016, Occurrence of PDL1/2 copy number gains detected by FISH in adeno and squamous cell carcinomas of the lung and association with PDL1 overexpression in adenocarcinomas, JCO, 34, 3031, 10.1200/JCO.2016.34.15_suppl.3031 Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349 Gabrilovich, 2017, Myeloid-derived suppressor cells, Cancer Immunol. Res., 5, 3, 10.1158/2326-6066.CIR-16-0297 Hirsch, 2017, PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project, J. Thorac. Oncol., 12, 208, 10.1016/j.jtho.2016.11.2228 Ratcliffe, 2017, Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer, Clin. Cancer Res., 23, 3585, 10.1158/1078-0432.CCR-16-2375 Tsao, 2017, Blueprint 2: PD-L1 immunohistochemistry comparability study in real-life, clinical samples Gadgeel, 2017, 1296OClinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study, Ann. Oncol., 28 Rimm, 2017, A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer, JAMA Oncol., 3, 1051, 10.1001/jamaoncol.2017.0013 Cheung, 2016, Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine: part 4: tissue tools for quality assurance in immunohistochemistry, Appl. Immunohistochem. Mol. Morphol. Cheung, 2017, Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine: part 1: fit-for-purpose approach to classification of clinical immunohistochemistry biomarkers, Appl. Immunohistochem. Mol. Morphol., 25, 4, 10.1097/PAI.0000000000000451 Torlakovic, 2017, Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine. part 3: technical validation of immunohistochemistry (IHC) assays in clinical IHC laboratories, Appl. Immunohistochem. Mol. Morphol., 25, 151, 10.1097/PAI.0000000000000470 Torlakovic, 2017, Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine − part 2: immunohistochemistry test performance characteristics, Appl. Immunohistochem. Mol. Morphol., 25, 79, 10.1097/PAI.0000000000000444 Sheng, 2016, Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer, Sci. Rep., 6, 20090, 10.1038/srep20090 Galluzzi, 2015, Immunological effects of conventional chemotherapy and targeted anticancer agents, Cancer Cell, 28, 690, 10.1016/j.ccell.2015.10.012 Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin. Cancer Res., 20, 5064, 10.1158/1078-0432.CCR-13-3271 Midha, 2016, PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age, JCO, 34, 3025, 10.1200/JCO.2016.34.15_suppl.3025 Rebelatto, 2016, Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma, Diagn. Pathol., 11, 95, 10.1186/s13000-016-0545-8 Skov, 2017, Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx, Appl. Immunohistochem. Mol. Morphol., 10.1097/PAI.0000000000000540 Lerner, 2017, PD-L1 assessment in FNA (EBUS) dervied samples, JCO, 35, 11615, 10.1200/JCO.2017.35.15_suppl.11615 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Loi, 2017, Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086, Ann. Oncol., 28, 10.1093/annonc/mdx440.005 Dieci, 2017, Semin. Cancer Biol. Hendry, 2017, Adv. Anat. Pathol., 24, 235, 10.1097/PAP.0000000000000162 Hendry, 2017, Adv. Anat. Pathol., 24, 311, 10.1097/PAP.0000000000000161 Higgs, 2016, Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients, JCO, 34, 3036, 10.1200/JCO.2016.34.15_suppl.3036 Wallden, 2016, Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System, JCO, 34, 3034, 10.1200/JCO.2016.34.15_suppl.3034 Antonia, 2016, Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer, JCO, 34, 9029, 10.1200/JCO.2016.34.15_suppl.9029 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Peters, 2017, Abstract CT082: impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026, Cancer Res., 77, CT082, 10.1158/1538-7445.AM2017-CT082 Johnson, 2016, Targeted next generation sequencing identifies markers of response to PD-1 blockade, Cancer Immunol Res, 4, 959, 10.1158/2326-6066.CIR-16-0143 Gandara, 2017, Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK), Ann. Oncol., 28, v460, 10.1093/annonc/mdx380 Spigel, 2016, Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies, JCO, 34, 9017, 10.1200/JCO.2016.34.15_suppl.9017 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 Turajlic, 2017, Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis, Lancet Oncol., 18, 1009, 10.1016/S1470-2045(17)30516-8 Champiat, 2017, Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin. Cancer Res., 23, 1920, 10.1158/1078-0432.CCR-16-1741 Kato, 2017, Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate, Clin. Cancer Res. Spitzer, 2017, Systemic immunity is required for effective cancer immunotherapy, Cell, 168, 487, 10.1016/j.cell.2016.12.022 Kamphorst, 2017, Proliferation of PD-1+ CD8T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc. Natl. Acad. Sci. U. S. A., 114, 4993, 10.1073/pnas.1705327114 Oh, 2016, Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients, JCO, 34, 3029, 10.1200/JCO.2016.34.15_suppl.3029 Routy, 2017, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science Vetizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329 Wargo, 2017, Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy, JCO, 35, 3008, 10.1200/JCO.2017.35.15_suppl.3008 Vandenbroeck, 2016 Van Dyck, 2016 Karasaki, 2017, An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer, J. Thorac. Oncol., 12, 791, 10.1016/j.jtho.2017.01.005 Salgado, 2017, Societal challenges of precision medicine: bringing order to chaos, Eur. J. Cancer, 84, 325, 10.1016/j.ejca.2017.07.028 Pignatti, 2014, Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union, Clin. Cancer Res., 20, 1458, 10.1158/1078-0432.CCR-13-1571 Pignatti, 2015, Assessment of benefits and risks in development of targeted therapies for cancer–The view of regulatory authorities, Mol. Oncol., 9, 1034, 10.1016/j.molonc.2014.10.003 Garassino, 2016, PL04a.03: durvalumab in 3rd-line locally advanced or metastatic, EGFR/ALK wild-Type NSCLC: results from the phase 2 ATLANTIC study, J. Thorac. Oncol., 12, S10, 10.1016/j.jtho.2016.11.012